Roche (RHHBY) reported a 6% increase in group sales at constant exchange rates, with a 7% rise in CHF, fueled by strong demand for its innovative medicines and advanced diagnostic solutions. This growth marks a solid start to the year for the healthcare giant.
Key developments include the progression of two promising therapies into phase III trials. One is an investigational Brainshuttle bispecific antibody designed for Alzheimer’s treatment, and the other is a next-gen medicine for haemophilia A. Additionally, Roche is collaborating with Zealand Pharma to advance amylin as a potential treatment for weight loss and as part of a fixed-dose combination with incretin CT-388.
In the Diagnostics division, Roche has introduced a pioneering 'sequencing by expansion' technology, which promises exceptional speed, flexibility, and accuracy. This innovation aims to enhance Roche's capabilities in meeting the evolving needs of healthcare.
Expanding its footprint in the US, Roche is making a significant investment of $50 million. This expansion supports their commitment to delivering cutting-edge medicines and diagnostics to American patients. With a workforce of over 25,000 and numerous research and manufacturing sites across the country, Roche is well-positioned to sustain its positive trajectory.
The company remains optimistic about maintaining this momentum and has reaffirmed its outlook for the full year.
